Budesonide can cause weight gain, but the risk depends heavily on how you take it, which formulation you use, and how long you stay on it. As a corticosteroid, budesonide shares the same basic mechanism that links all steroids to fat accumulation, but its unusual metabolism in the liver means far less of the drug reaches the rest of your body compared to older steroids like prednisolone. That distinction matters a lot in practice, though it does not make the risk zero for everyone.
Why Budesonide Behaves Differently From Other Steroids
Budesonide is a potent corticosteroid that your gut absorbs well, but most of it gets broken down during its first trip through the liver before it ever reaches general circulation. Roughly 85 to 95 percent of an oral dose is cleared in this “first-pass” metabolism step, which drastically limits how much active drug spreads through your bloodstream.1PubMed Central. Adrenal Insufficiency After Treatment With Budesonide: A Case Report and Literature Review That is the whole reason budesonide was developed in the first place: doctors wanted a steroid that could fight inflammation locally, in the gut or lungs, without triggering as many of the body-wide side effects that older steroids are infamous for.
This liver clearance is the main reason budesonide is favored over prednisolone for conditions like inflammatory bowel disease. Studies consistently show significantly less suppression of the adrenal glands with budesonide, meaning the body’s own hormone system stays more intact.1PubMed Central. Adrenal Insufficiency After Treatment With Budesonide: A Case Report and Literature Review Since steroid-related weight gain is driven by systemic glucocorticoid exposure, this lower systemic availability is directly relevant to the weight question. But “lower” is not “none,” and in certain situations that first-pass safety net gets overwhelmed.
What Happens With Oral Budesonide
The clearest evidence for weight gain comes from oral budesonide taken for gut-related or kidney-related conditions. A Cochrane systematic review of budesonide for maintaining remission in Crohn’s disease listed weight gain among the commonly reported treatment-related adverse effects, alongside things like acne, moon face, mood swings, and insomnia.2PubMed Central. Budesonide for maintenance of remission in Crohn’s disease The review did not quantify how many patients gained weight or how much, but the fact that it showed up consistently across multiple trials as a recognized side effect means it is not rare.
The most striking numbers come from a specific targeted-release formulation of budesonide used for IgA nephropathy, a kidney disease. In that study, about 64 percent of patients experienced weight gain, and roughly 55 percent developed facial swelling.3PubMed Central. A Targeted-Release Formulation of Budesonide for the Treatment of IgA Nephropathy Patients With Severe Renal Impairment Those rates are far higher than what is typically seen with budesonide for bowel conditions, and the difference likely reflects the specific formulation, dosing, and the underlying kidney impairment of the patients studied. Severe kidney disease can alter how drugs are metabolized, potentially increasing how much active budesonide reaches the bloodstream. The takeaway is that the same drug, delivered in a different way or to patients with compromised organ function, can produce very different side effect profiles.
Meanwhile, a four-year study of budesonide oral suspension for eosinophilic esophagitis found that the most common drug-related concerns were abnormal adrenal test results and adrenal insufficiency, not weight gain specifically.4PubMed. Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study This contrast is useful because it shows that the weight gain signal is not universal across every oral budesonide formulation. The formulation designed for the esophagus delivers the drug to a different part of the digestive tract and may result in different systemic absorption patterns.
How Budesonide Compares to Prednisolone
If you are being offered budesonide, one of the first things worth knowing is how it stacks up against the steroid it is usually replacing. A retrospective study of patients with autoimmune hepatitis found that those treated with prednisolone had a significantly larger increase in body mass index by the end of treatment compared to those on budesonide. The prednisolone group’s BMI rose by an average of about 1.5 points, while the budesonide group’s rose by about 0.3 points.5Gut. P38 Budesonide use results in less weight gain than prednisolone during the management of autoimmune hepatitis; results from long term follow up That is a roughly five-fold difference in BMI impact, and it reached statistical significance.
A real-world observational study in ulcerative colitis drew an even sharper line. Patients on prednisolone reported moon face, weight gain, insomnia, and acne, while patients on budesonide MMX reported none of those side effects.6Journal of Crohn’s and Colitis. P1139 A real-world, observational study comparing the side effects of budesonide MMX with prednisolone and the resolution of symptoms in patients with mild to moderate ulcerative colitis The zero weight gain reports in the budesonide group is encouraging, though this was a relatively small real-world study, not a large randomized trial, so the absence of reports does not guarantee the absence of the effect entirely.
The overall pattern across multiple conditions is consistent: budesonide produces less weight gain than prednisolone. It does not always produce zero weight gain, but the gap between the two drugs is meaningful and consistent enough that it is one of the primary reasons doctors choose budesonide when they can.
Inhaled and Nasal Budesonide
Millions of people use budesonide not as a pill but as an inhaler for asthma or a nasal spray for allergies, and the weight-gain picture looks very different for these formulations. When you inhale budesonide, only a small fraction makes it into your bloodstream. Nasal budesonide formulations have systemic availability ranging from about 13 to 29 percent of the metered dose depending on the delivery device, with aqueous pump sprays allowing more absorption than pressurized aerosols.7PubMed Central. Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder These percentages refer to the amount that reaches the bloodstream, which is then further reduced by liver metabolism. The net systemic exposure is very low.
For inhaled budesonide used in asthma, the main concern studied has been growth in children, not weight gain in adults. Research has found a small, dose-dependent slowing of growth velocity in kids using inhaled corticosteroids, with some differences between specific drugs and between individual children.8PubMed Central. The effects of inhaled corticosteroids on growth in children Clinically significant weight gain from standard-dose inhaled budesonide has not emerged as a prominent concern in the adult asthma literature. If you are using a budesonide inhaler for asthma or a nasal spray for allergies at normal doses, weight gain is very unlikely to be driven by the medication itself.
That said, poorly controlled asthma or allergies can themselves affect activity levels and sleep quality, which can indirectly influence weight. And some people on inhaled budesonide also take periodic courses of oral steroids during flare-ups. If you notice weight changes while using an inhaler, it is worth looking at the full medication picture rather than pointing solely at the inhaled budesonide.
When the Liver Safety Net Fails
The promise of budesonide rests on that 85-to-95-percent liver clearance, but several situations can undermine it. The most important is liver disease. When the liver is not functioning well, first-pass metabolism slows down, and more active budesonide enters general circulation. One study of budesonide in autoimmune hepatitis found that clinically relevant side effects showed up specifically in patients who had liver cirrhosis.9PubMed Central. Budesonide induces complete remission in autoimmune hepatitis For this reason, budesonide is generally avoided or used cautiously in patients with significant liver scarring. If you have cirrhosis and are prescribed budesonide, your systemic exposure could be much higher than what the drug’s safety profile was built around.
Drug interactions create a similar problem. Budesonide is broken down in the liver by a specific enzyme system. Drugs that inhibit that system, including certain antifungals, some antibiotics, and grapefruit juice in large quantities, can slow the breakdown and raise circulating budesonide levels. There have been documented cases of full-blown Cushing’s syndrome, a condition characterized by weight gain, a rounded face, high blood sugar, and thin skin, developing in patients on budesonide combined with drugs that block this enzyme pathway.10PubMed Central. Budesonide-Related Iatrogenic Cushing’s Syndrome in Microscopic Colitis These cases are uncommon but serve as a reminder that the “low systemic availability” label assumes a normally functioning liver working without pharmacological interference.
Who Is More Susceptible to Steroid-Related Weight Gain
A large population-based study tracking over 100,000 people over time found that individuals starting any new corticosteroid use gained more weight per year than non-users. The effect was modest in absolute terms, but it was statistically real. More revealing were the subgroup findings: the weight gain signal was driven primarily by women and by people whose BMI was already 25 or above. Men and people with lower starting BMI did not show the same pattern.11PubMed Central. Corticosteroid Use and Long-Term Changes in Weight and Waist Circumference: The Lifelines Cohort Study The same study found that systemic corticosteroid use was associated with increased waist circumference, suggesting that the weight effect concentrates around the midsection, consistent with how glucocorticoids promote fat storage in visceral (abdominal) tissue.
Encouragingly, the study also found that stopping corticosteroids was associated with a decrease in waist circumference over time.11PubMed Central. Corticosteroid Use and Long-Term Changes in Weight and Waist Circumference: The Lifelines Cohort Study That suggests the effect is at least partially reversible. If you gained weight while on budesonide and then stopped the drug, some of that abdominal weight accumulation can be expected to recede, though the timeline varies from person to person.
This study looked at corticosteroids broadly, not budesonide specifically, so caution is warranted in applying these numbers directly. But the biological mechanism, glucocorticoids driving fat storage preferentially in visceral tissue, applies to budesonide as well when systemic exposure is high enough. The practical implication is clear: if you are a woman with a BMI in the overweight or obese range, you may want to discuss monitoring strategies with your doctor if you are starting oral budesonide for a longer course.
How Glucocorticoids Actually Drive Fat Accumulation
All corticosteroids, budesonide included, can promote weight gain through the same basic pathway when enough of the drug reaches the bloodstream. Glucocorticoids stimulate appetite, promote the storage of fat (especially around the abdomen and face), and can raise blood sugar levels in a way that further encourages fat deposition. Research has shown that glucocorticoids work through molecular partners in visceral fat tissue that specifically drive the creation of new fat cells in abdominal depots.12Cell Metabolism. Human visceral-fat-specific glucocorticoid tuning of adipogenesis This is why corticosteroid weight gain tends to have a characteristic pattern: the face rounds out, the belly expands, while the arms and legs may not change much or may even thin.
The duration of exposure matters as much as the dose. Short courses of a few weeks carry lower risk than months or years of continuous therapy. One important limitation across the corticosteroid research is that many studies have incomplete data on cumulative dose and duration, making it difficult to draw precise thresholds for when weight gain becomes likely.13PubMed Central. Systematic Evaluation of Corticosteroid Use in Obese and Non-obese Individuals: A Multi-cohort Study In general, though, the shorter the course and the lower the dose, the less likely you are to notice changes on the scale.
Practical Steps If You Are Concerned
If your doctor has recommended budesonide, refusing it out of weight-gain fear is usually the wrong call, especially for conditions like Crohn’s disease, eosinophilic esophagitis, or autoimmune hepatitis where uncontrolled inflammation can cause far worse problems than a few extra pounds. The more productive approach is to understand your personal risk and plan accordingly.
A few things worth discussing with your prescriber:
- Formulation: Inhaled and nasal budesonide carry minimal weight risk at standard doses. Oral formulations carry more, with targeted-release versions for kidney disease appearing to carry the most.
- Duration: Short induction courses of a few weeks are less likely to cause noticeable weight changes than months of maintenance therapy.
- Liver health: If you have any degree of liver disease, your doctor should know before starting budesonide, because impaired liver function can sharply increase systemic exposure.
- Other medications: Make sure your prescriber has a complete list of everything you take, including antifungals and supplements, to screen for interactions that could raise budesonide levels.
Tracking your weight weekly rather than daily gives a clearer signal if changes are happening, since daily fluctuations from water and food can obscure a real trend. If you do notice a steady upward drift of a few pounds over weeks, that is worth mentioning at your next visit. Early awareness gives your doctor the chance to adjust dosing or explore alternative maintenance strategies before the gains compound.
The IgA Nephropathy Outlier
The strikingly high rate of weight gain seen in the IgA nephropathy study, where nearly two-thirds of patients reported it, deserves its own context.3PubMed Central. A Targeted-Release Formulation of Budesonide for the Treatment of IgA Nephropathy Patients With Severe Renal Impairment These patients had severe kidney impairment, which can alter drug metabolism and fluid balance independently of the steroid itself. Fluid retention from kidney disease can show up as weight gain on a scale even when fat mass has not changed. The targeted-release capsule used in this study is designed to deliver budesonide to a specific part of the small intestine near immune tissue related to IgA production, and may result in different absorption kinetics compared to the enteric-coated capsules used for Crohn’s disease.
If you are a Crohn’s or ulcerative colitis patient reading that 64 percent figure and feeling alarmed, understand that it almost certainly does not apply to you. The population, formulation, and underlying organ function are all different. Your risk profile with standard enteric-coated oral budesonide is substantially lower, and head-to-head data against prednisolone consistently shows budesonide coming out ahead on weight-related side effects.
When Weight Changes Are Not Actually From Budesonide
People with chronic inflammatory conditions often experience weight fluctuations from the disease itself. Active Crohn’s disease can cause malabsorption and weight loss, so gaining weight during a remission course of budesonide may partly reflect the gut healing and absorbing nutrients properly again. Similarly, someone whose eosinophilic esophagitis made swallowing painful may eat more once the inflammation subsides. Attributing all weight change to the drug overlooks the fact that effective treatment often restores normal eating patterns.
Fluid retention is another confound. Corticosteroids at higher systemic levels can cause sodium and water retention, which adds scale weight quickly but is not the same as fat gain. If you notice puffiness in your ankles, hands, or face within the first week or two of starting budesonide, that is more likely fluid than fat, and it tends to resolve after the course ends or the dose is reduced. True fat gain from glucocorticoid-driven metabolic changes takes longer to develop and follows a more gradual trajectory.
Separating these different types of weight change matters because the management strategies differ. Fluid retention responds to dose adjustments and dietary sodium reduction. Disease-related appetite recovery is a sign of healing, not a side effect. And genuine steroid-driven fat deposition is the one that may require a conversation about switching medications or adjusting the treatment plan.